Your browser doesn't support javascript.
loading
Engineered Newcastle disease virus expressing the F and G proteins of AMPV-C confers protection against challenges in turkeys.
Hu, Haixia; Roth, Jason P; Zsak, Laszlo; Yu, Qingzhong.
Afiliação
  • Hu H; College of Animal Science and Technology, Southwest University, Chongqing, 400715, China.
  • Roth JP; Southeast Poultry Research Laboratory, US National Poultry Research Center, Agricultural Research Services, United States Department of Agriculture, 934 College Station Road, Athens, GA, 30605, USA.
  • Zsak L; Southeast Poultry Research Laboratory, US National Poultry Research Center, Agricultural Research Services, United States Department of Agriculture, 934 College Station Road, Athens, GA, 30605, USA.
  • Yu Q; Merial Ltd., 1730 Olympic Dr., Athens, GA, 30601, USA.
Sci Rep ; 7(1): 4025, 2017 06 22.
Article em En | MEDLINE | ID: mdl-28642611
Avian metapneumovirus (AMPV) infects the respiratory and reproductive tracts of domestic poultry, resulting in substantial economic losses for producers. Live attenuated vaccines appear to be the most effective in countries where the disease is prevalent. However, reversion to virulence has been demonstrated in several studies. Therefore, the development of a stable and safe next generation vaccine against the AMPV disease is needed. In the present study, we generated a recombinant Newcastle disease virus (NDV) vectoring the fusion (F) protein and glycoprotein (G) genes of AMPV subtype-C (AMPV-C) as a bivalent vaccine candidate using reverse genetics technology. The recombinant virus, rLS/AMPV-C F&G, was slightly attenuated in vivo, yet maintained similar characteristics in vitro when compared to the parental LaSota virus. Vaccination of turkeys with rLS/AMPV-C F&G induced both AMPV-C and NDV-specific antibody responses, and provided significant protection against pathogenic AMPV-C challenge and complete protection against velogenic NDV challenge. These results suggest that the rLS/AMPV-C F&G recombinant virus is a safe and effective bivalent vaccine candidate and that the expression of both F and G proteins of AMPV-C induces a protective response against the AMPV-C disease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vírus da Doença de Newcastle / Vacinas Virais / Proteínas do Envelope Viral / Proteínas Virais de Fusão / Metapneumovirus / Vetores Genéticos Limite: Animals Idioma: En Revista: Sci Rep Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Vírus da Doença de Newcastle / Vacinas Virais / Proteínas do Envelope Viral / Proteínas Virais de Fusão / Metapneumovirus / Vetores Genéticos Limite: Animals Idioma: En Revista: Sci Rep Ano de publicação: 2017 Tipo de documento: Article